Clinical Research Directory

Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients

Sponsor: Peking Union Medical College Hospital

Summary

There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur. While rivaroxaban typically doesn't require coagulation monitoring, in elderly patients, particularly those with multiple medications, finding appropriate lab indicators becomes crucial to gauge its anticoagulant effect. This aids in evaluating precise rivaroxaban dosing for the elderly, balancing bleeding risks and recurrence. Clinical pharmacological studies suggest that drug pharmacokinetics and pharmacodynamics in different populations can guide dosage optimization. Hence, this study aims to provide a basis for optimizing dosing regimens in high-risk elderly patients in China by exploring pharmacokinetic and pharmacodynamic indicators in clinical practice.

Official title: The Exploratory Study on Clinical Rational Use of Rivaroxaban Dosing in Elderly Chinese Population

Key Details

Conditions

Interventions

Locations (1)